All In Biotech

Drug Trial Radar · NCT07190300

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 181 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

181

Planned (sponsor's estimate)

Start

Jan 13, 2026

Primary completion

Aug 2, 2032

Study completion Aug 2, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer (mHSPC). Phase I aims to determine the recommended dose(s) for expansion (RDE) of tulmimetostat in combination with darolutamide or abiraterone. Phase II is designed to further evaluate the efficacy and safety of tulmimetostat in combination with darolutamide compared with darolutamide alone in participants with mHSPC.

Conditions

  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

  • TulmimetostatDrug

    Tulmimetostat is an oral dual EZH1/EZH2 inhibitor administered once daily. In Phase I, escalating dose levels will be evaluated in combination with darolutamide or abiraterone. In Phase II, one or two dose levels selected from Phase I will be evaluated in combination with darolutamide.

  • DarolutamideDrug

    Darolutamide 600 mg administered orally twice daily (BID).

  • AbirateroneDrug

    Abiraterone 1000 mg administered orally once daily (QD) in combination with prednisone/prednisolone according to local prescribing information.

  • Prednisone/PrednisoloneDrug

    Oral corticosteroid administered with abiraterone in Phase I Group B according to local prescribing information.

  • Androgen Deprivation Therapy (ADT)Drug

    Background therapy consisting of a gonadotropin-releasing hormone (GnRH) agonist/antagonist or prior orchiectomy to maintain castrate testosterone levels (\<50 ng/dL \[\<1.7 nmol/L\]). All participants will continue ADT throughout study participation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I (Group A and Group B): Dose-limiting toxicities (DLTs)Time frame: From the first dose of study treatment through the end of Cycle 1, up to 28 days
  2. Phase I (Group A and Group B): Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
  3. Phase I (Group A and Group B): Number of Participants with dose adjustmentsTime frame: From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
  4. Phase I (Group A and Group B): Dose IntensityTime frame: From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
  5. Phase I (Group A and Group B): Duration of exposure to each study drugTime frame: From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months
  6. Phase II (Group A): Prostate-Specific Antigen (PSA) response rate of < 0.2 ng/mL at Month 6Time frame: At Month 6, with confirmation by a second prostate-specific antigen assessment performed at least 3 weeks later

Locations

31 sites in 14 countries. Site status is shown where the registry gives one.

  • Univ of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Uni Of Iowa Hospitals And Clinics

    Iowa City, Iowa · Recruiting

  • University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Wichita Urology Group PA

    Wichita, Kansas · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Medical University of South Carolina MUSC

    Charleston, South Carolina · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Novartis Investigative Site

    Camperdown, New South Wales, Australia · Withdrawn

  • Novartis Investigative Site

    Wollongong, New South Wales, Australia · Recruiting

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Guangzhou, China · Recruiting

  • Novartis Investigative Site

    Créteil, France · Recruiting

  • Novartis Investigative Site

    Lille, France · Recruiting

  • Novartis Investigative Site

    Nantes, France · Recruiting

  • Novartis Investigative Site

    Essen, Germany · Recruiting

  • Novartis Investigative Site

    Jena, Thuringia, Germany · Recruiting

  • Novartis Investigative Site

    Hong Kong, Hong Kong · Recruiting

  • Novartis Investigative Site

    Budapest, Hungary · Recruiting

  • Novartis Investigative Site

    Budapest, Hungary · Recruiting

  • Novartis Investigative Site

    Szeged, Hungary · Recruiting

  • Novartis Investigative Site

    Rozzano, MI, Italy · Recruiting

  • Novartis Investigative Site

    Verona, VR, Italy · Active not recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Ankara, Sihhiye Altindag, Turkey (Türkiye) · Recruiting

  • Novartis Investigative Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.